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CARDIAC PROTEIN RGS2: STRUCTURAL AND FUNCTIONAL DETERMINANTS 
Advisor-Dr. Brett Adams, Department of Biology, Utah State University 
INTRODUCTION: 
In this study, I explored the structure-function relationships of a cardiac RGS (regulator 
of G-protein signaling) protein, RGS2. 
Contractions of the heart are triggered by calcium ions (Ca) entering heart cells through 
L-type Ca channels (1 a). The activity of L-type channels (and thereby Ca influx) is modulated 
by cell surface receptors that couple to intracellular G proteins. G proteins in turn, are regulated 
by a newly-discovered family of proteins called RGS. RGS proteins speed the hydrolysis of 
GTP by G proteins, and thereby control the strength and duration of G protein-mediated signals. 
Stimulation of G proteins, which are coupled to receptors , can alter the rate of heart contractions 
(2). 
Contraction rate of heart cells is important for several reasons. Namely, a slower, 
controlled contraction rate, or heartbeat, pumps oxygenated blood throughout the body more 
efficiently than a fast contraction rate. It has been shown that inadequate blood flow through the 
heart is directly correlated with deficiency of calcium channel stimulation (lb). Several RGS 
proteins are expressed in heart, but their physiological significance and ability to affect influx of 
calcium ions through calcium channels has been largely unexplored. This study reveals new 
insights into the structure /function relationships of RGS2. These insights may be helpful m 
understanding the molecular basis of certain cardiovascular diseases. 
DETAILED EXPLANATION: 
Proteins in the RGS2 family are composed of a highly conserved core region and variable 
terminal regions (3). My major objective was to determine the functional importance of the 
RGS2 non-core regions (N-terminus and C-terminus). I used the polymerase chain reaction 
(PCR) to construct mutant RGS2 proteins lacking the amino-tenninus, the carboxyl-terminus, or 
both. These mutant RGS2 proteins were expressed in a cell line and their abilities to influence 
L-type Ca channel activity were determined via electrophysiological experiments. RGS proteins 
speed up the rate of GTP hydrolysis by 100-fold, the inhibition of extracellular calcium should 
decrease the rate of heart contraction . Thus , we expected their presence to inhibit the influx of 
extracellular calcium into the cell. 
Cell culture methods were employed to maintain mammalian HEK293 cells for 
transfection with normal RGS2 and RGS2 core. Cardiac calcium current was measured via 
patch-clamp recording. Patch-clamp recording was used to measure whole-cell Ca channel 
currents and current inhibition during activation of coexpressed M 1 muscarinic acetylcholine 
receptors . Through the use of specifically designed oligonucleotide primers, we amplified only 
the core region of RGS2. The primers contained restriction enzyme sites to facilitate insertion of 
the RGS2 core into an expression vector. The PCR product was gel purified and digested with 
restriction enzymes corresponding to the primer enzyme sites. The digested PCR product was 
then ligated into the bicistronic mammalian expression vector pIRES-2, which independently 
expresses green fluorescent protein as a transfection marker. Alternatively, transfected cells 
were identified by cotransfection with an expression plasmid encoding the cell surface antigen 
CD8. We found that RGS2 prevents channel inhibition by Ml receptors, and that the RGS2 core 
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does not prevent channel inhibition. Thus, structural regions flanking RGS2 core are required 
for proper function of RGS2. The functional importance of other structural regions of RGS2 are 
presently being analyzed. 
REFERENCES: 
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2. Neer, El Heterotrimeric G Proteins: Organizers of Transmembrane Signals. Cell 
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Chem. 1998; 273(3): 1269-1272. 
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OTHER IMPORTANT WORK WITH DR. BRETT ADAMS: 
From a summer research program during high school, I was able to gain a familiarity with basic 
lab procedures. This allowed me to begin meaningful work as an assistant in various projects 
once I began in Dr. Adams' lab as a freshman at Utah State University. My work included 
animal dissection of adult and neonatal organs (i.e., heart ventricle and dorsal root ganglia) and 
establishing primary cell cultures from these organs. My work also entailed various basic 
procedures such as purifying DNA, growing bacterial cultures, etc. 
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PROTEIN II TRANSCRIPTION FACTOR OF APOLIPOPROTEIN B 
Advisor-Dr. Joan Hevel, Depa1tment of Chemistry & Biochemistry, Utah State University 
INTRODUCTION: 
Protein involvement in human disease is on the forefront of proteomic research. Proteins 
are involved in a multitude of mammalian cellular processes. Structure-function relationships 
govern the responsibilities of both structural and enzymatic proteins. Advancement in proteomic 
research over the past five years has enabled researchers to begin ascribing function to the 
extensive array of human proteins. Understanding these functions is critical to determining 
variation in protein function when the cellular environment is in a diseased, stressed, or 
cancerous state. It is especially important to detern1ine what causes proteins themselves to 
trigger disease. 
Medical researchers are now implicating specific proteins in leading to cardiovascular 
disease (CVD) ( 1 ). CVD has become an umbrella-term for the myriad of problems that develop 
in the vascular system due to its domino-effect of decreasing the efficiency of other organs. This 
makes treatment very difficult as the disease progresses and is one reason CVD has become an 
epidemic in the United States. Cholesterol deposition is one main cause of CVD in humans. 
LDL (Low-Density Lipoprotein) is one of the main components involved in causing cholesterol 
deposition. My interest has been in studying LDL, whose main component is ApoB 
(Apoliprotein B). Transcription of ApoB takes place when transcription factors bind to DNA 
encoding the specific gene. These transcription factors are protein molecules which possess 
consensus sequences for binding to DNA. It is hoped that understanding protein-DNA 
interactions that trigger synthesis of harmful molecules will lead to measures of therapeutic 
intervention. Because ApoB can only be synthesized after the action of sequence-specific DNA-
binding proteins, my specific goal has been to identify the second of three binding proteins 
necessary for transcription of ApoB. (The first and third binding proteins are already known.) 
This project is being currently being pursued under the supervision of Dr. Joan Hevel, 
Department of Chemistry and Biochemistry, Utah State University. Hopefully, therapeutic 
strategies may be developed in response to present research in proteomics. 
DETAILED EXPLANATION: 
DLD (Low-Density Lipoprotein) transports cholesterol in the blood; high levels of blood 
LDL are correlated to risk of heart disease (2). LDL's lipid/protein structure contains a major 
component-Apolipoprotein B (ApoB). Because ApoB is a precursor to LDL synthesis, it is 
confirmed that blood levels of ApoB are a better predictor of cardiovascular disease (CVD) risk 
than LDL blood levels (for which millions of Americans are currently screened every year) (3). 
Production of ApoB requires transcription of the ApoB gene. Transcription, like many 
biological processes, involves the action of sequence-specific DNA-binding proteins. In the case 
of ApoB, there are three binding proteins; two known (HNF I-alpha, C/EBP) and one unknown 
( called "Protein II"). The binding sites for these three proteins are located on the core enhancer 
of the ApoB gene. Essentially, these proteins act as gatekeepers to beginning the synthesis of 
ApoB. They must be bound to thefr respective binding sites on the enhancer for transcription of 
ApoB to occur. It has been shown that binding HNF-1-alpha is necessary for full activity of the 
ApoB enhancer in HepG2 cells; wlhen HNF I-alpha binding does not occur, activity of the core 
enhancer decreases by 80% ( 4 ). Itt was also shown that binding of C/EBP is necessary for full 
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activity of the enhancer. Mutagenesis of HNF-1 alpha and/or C/EBP binding sites shows that 
binding of both these proteins is essential for full ApoB gene expression (5). The third 
component necessary for full activity of the core enhancer , Protein II, remains relatively 
unexplored. Disruption of Protein II binding also diminishes the capacity of enhancer activity. 
Although work has been done to identify both proteins HNF-lalpha and C/EBP, the identity of 
Protein II is yet to be discovered. Currently, my work seeks to 1) design an affinity resin based 
on the sequence that binds Protein II (via DNA affinity chromatography); 2) purify protein II 
using the designed affinity resin; and, 3) characterize Protein II by mass spectrometry to discern 
the identity and perhaps the specific function of Protein II in enhancing transcription of ApoB. 
Using the DNA sequence of the Protein II binding site, we will design a sequence-based affinity 
resin using an established method (6). The designed affinity resin will allow us to isolate Protein 
II from a mixture of several proteins in HepG2 cells. Protein II can then be enzymatically 
digested to obtain its peptide components and characterized using mass spectrometry. Data from 
the mass spectral analysis will be used to perform database searchers to identify Protein II. After 
the identity of Protein II is known, we will classify the functional regions of the protein in order 
to discern how its binding to the enhancer region of ApoB increases transcription of ApoB. 
Because transcription of the ApoB gene s regulated in a tissue-specific manner, this project will 
also provide insights into the regulation of tissue-specific gene expression. 
My results will increase understanding of structure-function relationships in order to 
eventually control synthesis of ApoB through the use of specifically designed antagonist 
molecules. These results will also increase our understanding of how levels of LDL are 
regulated in the body , leading to better understanding of what causes proteins to initiate synthesis 
of harmful molecules. 
Through continued research into protein biochemistry, I hope to contribute to our current 
knowledge of cardiovascular health. 
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Cardiovascular Disea se Risk: Beyond Low-Density Lipoprotein Cholesterol. American 
Association of Occupational Health Nurses. 2003. 51(12):521-31. 
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Lipoprotein in Cholesterol With Other Cardiovascular Risk Factors In The Insulin 
Resistance Atherosclerosis Study (IRAS). Circulation. 2003. 108(19):2132-2316. 
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Sequences Containing the Second-Intron Enhancer Are Essential for Transcription of the 
Human Apolipoprotein B Gene in the Livers of Transgenic Mice. Molecular and Cellular 
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Cellular Biology. 1992. 12(3): 1134-1148 . 
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OTHER IMPORTANT WORK WITH DR. JOAN HEVEL: 
I have established a room for tissue culture within our research facility. My work has involved 
each step of the process-from design layout and ordering equipment to the actual culturing of 
cells. This working facility will soon serve five researchers in projects involving A549 lung cells 
in tissue culture experiments. 
Recently, my work with Dr. Hevel has explored the role 
Methylation) in apoptosis induction via RNAi experiments. 
following poster presentation (Student Showcase 2005). 
of PRMT6 (Protein Arginine 
This work is detailed in the 
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Cardiac RGS Protein Structural Determinants and Function 
Stephanie Chambers , Roger Bannister and Brett Adams 
Department of Biology, Utah State University, Logan, UT 84322 
Introduction 
Contractions of n,, h .. n ,,.. tr1gg,rtd by calcium k)n1 (Ca) ,nt,rtng h11rt 
etlll lhrollgh L-type C■ ch-,v,111. The activity ofL-type channels (and 
lhtreby C1 lnftu)() 11 modulated t,y c• • 1urf1u r,c,ptor1 that couple to 
lntr1c,nu11r mo11cul1r l'Mlches known as ·o prot11n1· (.Tor OTP-binding 
protein). G prol1tn1, In lum . art regulated by I newt)'-dlscov,,.d family o/ 
prol1tn1 Clllld RGS (tor [t9Uletor of 2 prol.in 11gn1llng). RGS proteins 
&pHd lht hydrolylls of OTP by G prot.ins , tl'ld thereby conlrol lM sl!'fflglh 
and dlntlon of G prottln-m1dlat1d Signals. s,....,., RGS proltlnl .... 
9X?fHHd In hHrt , bu! their physlologlcal slgn~tnct 11 currtnll)' unknown . 
In !ht prtunt study, we uplored !ht structurtA\mctlon ralltlonshlps of 1 
nn:ll■ c: RGS ptoltln, RGS2 . Wt used the pot-;m,11111 chain rHctlon (PCR) 
lo construct mutant RGS2 proteins ltc:klng !hf 1mlno-twmlnu1 , Iha 
carb~l1rmlnu1 , or both. ThtH mutant RGS2 pl'Qteln1 wel'I exp1"11Hd In 
• cell line Ind lhllr lblUtlH to lnftu,nc, L·typl Cl ehennel •ctMty wtr• 
determined In elect~lologlcal ex~ment1 . TNt study rew1t1 ntw 
lnllghtl Into the stNctur"1\lnctlon r,11t1on1hlp1 of RGS2. These ln1lgh11 
may be helpl\ll In i.mderllandlng th• molecular b11t1 oJ c,rtllln 
cardlov11cu11r dlHHH . 
~ 
To CMtermlne th, r1.mctlonll mpol1■ 1'1Ce ofth, RGS2 non-COl'I 
l'lglon1 (N-INmlnu1 end C-1,rmlmJI) 
.,.,.,,, 
Materials & Methods 
•Ollgonucleotta, pnm,rs wert dHlgned to amplify only the col'I region of 
RGS2. Thi p,1mers conl1lnld restriction •nZ)'ffle sites to fllcHNll• lnurtlon 
or the R.GS2 cort Into 1n exprHllon wctor . 
•Thi potym, ..... chain reaction (PCR) Ml UHd to amplty the RGS2 core 
region. 
• Th• PCR. product wes gel purified end digested wllh restrk:tlon enzymes 
corT9spondlng lo the primer enzyme snes. Th• digested PCR. product was 
thin Dgated Into th, blclllronlc m1mmllllen 1xpr11slon vector ptRES-2 
(Clont,ch), which tndep.ndenlty expr11s11 grHn fluorescent protein 11 • 
lr■n1flctlon marker. Altem10vety, lr1n1flcted cells wtr• ldenll\ld by 
cotr■nlf'ec:Uon with an expr11slon plesmld encoding tht cell slM'fec, 1nt'91n 
coe c, .g. Fig. 4) 
• Call cUllurt methods wtrt employt,d lo m1lnllln m1mm1ll1n HEK293 c1H1 
ror trantfedlon wllh RGS2 Ind RGS2 core. 
• PIich-Ciamp recording WH UHd lo fflH1ur, 'MlO,.ctl c, channal 
CUrT'9nlS end CUrT'9nl Inhibition dur1ng 1ctlvetlon of co,xprHHd M1 
mu1c1rtnlc acetytchoUn, r9ceptors. 
Polymerase Chain Reaction 
_,., , 
Figure 2. Gel Purification of PCR product 
PCB rnlt Plctm1110 : 
Each or 30 eyelet con11st1d of 1 
minute 111 915 °c lo allow 
separation of ONA llr1nds . 
followed by 1 minute It 155 °c to 
,How primers to anneal to 
template, followed by 1 minute II 
72 °c to allow eldentlon of new 
ONA strands. 
~ = 
0 .7% 1g1rou gel wllh elhldtum 
bttlmldl staining Wfl UHd lo 
cont\rm that the PCR product WIS 
th• expected i.ngth . A standard 
ONA ladder composed of ONA 
l't1gm1nls of known length (r.r 
rlghl) was used tor comp■rtson 
wllh the PCR prodUct (middle). 
PCR Cortrt:i ROS, ~CR ProclJC1 L10att 
Flgu~ 3. G protein cycle & signaling 
Figure 4. HEK293 cells and patch-clamp pipette 
,mc:11111W•-~)lrtCOlltdwtht11• C08 1n1illc4r1ncl• cktocllll 1•111-111gcllll-tu!ftc1ctllpi«...,11 1 
!rffilftc!JOftffl•tlm 
Figure 6. Electrophyslologlcal Results 
A a 
Do ccn Control 
j-02 ~ ,_,, 1 ,......_, 













conciuslona & Future Exceriments 
• RGS2 prewnts ch.wlel lnhlblllon Dy M1 rec1ptot1. 
• RGS2 cora doet not prevenl channel lnl'llbltlon. 
• Thul , structural regions nanldng RGS2 core are required for proper l\lnctlon of 
R.GS2. 
•Th• ft.mctlonll lmpo,tanc, of other slt\lcturel regions of RGS2 are preHntly being 
1nllyzed. 
Rm= 




Biochemistry Classifieds : Stealthy RNAi Seeking Att ractive PRMT6 
Stephanie J. Chambers, Department of Biology, Utah State University 
Joan M. Hevel, Department of Chemistry & Biochemistry, Utah State University 
Introduction 
The central dogma of llclence (one gene encodes lnfonnat lon for one protein, 
one protein perfonns one function) is changing as we clarify the role of post• 
trans1atlonat modifications (PTMs) . PTMs are changes to protein structure after 
assembly by the ribosome . PTMs allow an organism to expand Its functlonal 
proteome ; I.e ., create more function from a single gene . ?TM-dependent change 
In prote in f\.nctlon can dictate molecular messages In cellular signa Ung 
pathways . One class of enzymes that perfonns FTMs ls PRMT (Rroteln 1rglnlne 
fl)ethyltransferase) , which catalyms the methy\at1on of specl11c peptldyl arginine 
residues In select proteins. Our laboratory is currentty studying the 
methylarginine proteome of human A549 lung epllheHal cens In order to 
understand how each of the 8 human PRMTs may be Involved In cellular 
communication . 
~ 
Knock·do'wn expression of PRMT6 protein using RNA interference In human 
lung AS-48 eplthetial ceRs. Cen lysates 'MA be assessed for a) the presence of 
PRMT6 mRNA , b) PRMT6 protein and c) any altered change In the pattem of 
protein arginine methylallon . We hope to Identify which proteins are methylated 
by PRMT6 by comparing the methylargin lne proteome of control and RNAJ· 
treated cells . 
M!lll.odl 
ln our research , we performed an RNAi ([iboouclelc 1.cld interference ) 
experiment to knock•down PRMT6 express ion In human AS-49 epithelia l tung 
cells (See Figure 3). Introduction of double.stranded RNA (red/blue strand ) Into 
Figure 1. RNAJ Mechanism 
cells can suppress gene express ion 
by target ing specific mRNA 
sequences for degradation . The 
genera l mechanism by 'Which this 
occurs is shown In Figure 1 at left . 
stealthRNAi molecules (lnvitrogen ) 
were designed against PRMT6 based 
on pre"1ous protocols and use of 
lnvlt rogen 's o~Hne design program . 
lipofectamlne 2000 was used as a 
vehi cle to suspend the RNAI 
molecules and to aid In the uptake of 
ONA Into the ceNs. Antibodies to 
PRMT6 were purchased from 
lmmunige nex . Human AS-49 lung 
epithe lial ce0s were cultured In a 
12•weH plate . Cens at 50-60% 
confluency were treated with either 
media , lipofectamlne 2000 , Stealth 
RNAi or a scrambled Stealth RNAi 
molecule as a negative contro l as 
depicted in Figure 2. Cells were 
harvested after 72 hours of treatment , 
a soluble prote in lysate prepared , and 
the presence of PRMT6 assessed by 
West.em analysis . 
HrnlJtJ 
Figure 2. Weslern Blot Results from 12-Well Experiment 
Probed wlh anU-PRMT6 
8. RNAI A - Media+ RNA Vehicle+ RNAI 
g RNAI B - Media+ RNA Vehicle+ RNAI 
10. RNAJ C - Media+ RNA Vehkle + RNAI 
1415 




11. Scrambled A - Media+ RNA Vehicle+ Scrambled RNA.I 
12. Scrambled B - Media+ RNA Vehlcle + Scrambled RNAI 
13· Scrambled C - Media+ RNA Vehicle+ Scrambled RNA.I 
1, . Control D - Cytoplasmic tysate 
15• Marker 
Figure 3. Human Lung Carcinoma A&48 Cell 
lmmunoftuorescent 
labeling shows eel 
focal adhesion 
sites (green) , 
protein complexes 




• Given the current conditions , PRMT6 protein levels did not appear to 
change in A5-49 eels . 
Future Experiments 
• Asses the abiUty of the c1.1Tent conditions to decrease leve ls of PRMT6 
mRN.._, 
• Optimize cond itions for effective PRMT6 prote in knock•down . 
• Assess changes In methylatlon patterns tn the ceU after RNAI 
knockdown expe riments . 
• Assess phenotypic changes of PRMT6 knockdowns . 
Utah State 
UNIVERSITY . 
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